Brief: BLS Pharmaceuticals Sees FY27 Adjusted. EBITDA Margin 23% - 26%
31/08/2026 08:50
BRIEF-BLS Pharmaceuticals Sees FY27 Adjusted. EBITDA Margin 23% - 26% Aug 31 (Reuters) - BLS Pharmaceuticals Ltd BLS.AX:
SEES FY27 ADJUSTED. EBITDA MARGIN 23% - 26%
SEES FY27 REVENUE A$105M – A$115M
Further company coverage: BLS.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BLS Pharmaceuticals
See all newsBrief: BLS Pharmaceuticals Posts Q1 FY27 Revenue A$26.7M
Brief: BLS Pharmaceuticals Reports Record Q1 FY27 Revenue Of A$26.7 Million
Australia's BLS Pharmaceuticals extends gains on upbeat outlook, strong results
Brief: BLS Pharmaceuticals Sees FY27 Adjusted. EBITDA Margin 23% - 26%
Brief: BLS Pharmaceuticals Posts FY Net Profit After Tax Of A$15.4 MLN